top of page
Developing Novel, First in Class Drugs, Treating and Preventing
Type 2 Diabetes, Based on a Core-Technology-Platform.
Pipeline IND in process
Type 2 Diabetes Drug
Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use.
These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. Concenter BioPharma is developing and commercializing the drug which treats and prevents Type 2 Diabetes.
The drug has 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases
(and anecdotal human cases).
Prof. DeFronzo presentation audio at the 17th World Congress
on Insulin Resistance. Diabetes & Cardiovascular Disease 
Insulin Resistance All You Wanted to KnowProf. DeFronzo
ABOUT US & VISION
Becoming a global specialty biopharmaceutical company by advancing a pipeline of products that demonstrate vast potential for treating TYPE 2 DIABETES.
Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications.
Our PLATFORM is the result of extensive investigation of animal models of human diseases.
MEMBERS OF OUR PLATFORM ACT AS:
Potent anti-inflammatory agents, Strong iron-chelating agents, and Anti-biotic agents.
To rapidly advance from laboratory experiments to clinical trials in Type 2 Diabetes based on "shortcut"
regulatory routes, that enable a shorter time from the lab to treating patients.
Our initial focus is on a leveraging Expedited Pathway programs.
Our focus leverages the global demand-creating patient population of about 570 million people with Diabetes.
Our drug for treating Type 2 Diabetes (Pill) – extensively demonstrated as effective in both prevention and treatment of T2 Diabetes – by Restoring Insulin Resistance to Normal Levels!
Markedly inhibiting the appearance and the degree of hyperglycemia; lowering LDL; lowering body weight; reduction of cataract formation and diabetes-induced retinopathy.
bottom of page